According to Zacks, “Lannett Company manufactures and distributes high quality affordable generic medications that are the therapeutic equivalent of the brand-name pharmaceuticals. Their portfolio consists of numerous products across a wide range of therapeutic areas. Lannett believes that their ability to select viable products for development, efficiently develop such products, including obtaining any applicable regulatory approvals, vertically integrate themselves into certain specialty markets and achieve economies in production are all critical for their success in the generic pharmaceutical industry in which they operate. Lannett Company, Inc., continues to dedicate significant capital toward developing new products as they believe their success is linked to their ability to continually introduce new generic products into the marketplace. “
LCI has been the topic of a number of other reports. SunTrust Banks upped their target price on shares of Lannett from $10.00 to $14.00 and gave the company a hold rating in a report on Wednesday, September 18th. ValuEngine upgraded shares of Lannett from a strong sell rating to a sell rating in a report on Friday, January 3rd.
NYSE:LCI traded down $0.30 on Tuesday, reaching $9.75. The stock had a trading volume of 1,294,411 shares, compared to its average volume of 977,682. The company has a market cap of $405.29 million, a price-to-earnings ratio of 4.15 and a beta of 2.12. The company has a debt-to-equity ratio of 2.07, a current ratio of 2.43 and a quick ratio of 1.60. The firm’s fifty day moving average is $8.81 and its two-hundred day moving average is $9.20. Lannett has a 12-month low of $5.16 and a 12-month high of $15.52.
Lannett (NYSE:LCI) last released its earnings results on Wednesday, November 6th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.19 by $0.03. The company had revenue of $127.30 million for the quarter, compared to analyst estimates of $120.78 million. Lannett had a net margin of 0.52% and a return on equity of 25.40%. The firm’s quarterly revenue was down 17.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.44 EPS. As a group, research analysts forecast that Lannett will post 1.19 earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the business. Glen Harbor Capital Management LLC purchased a new position in shares of Lannett during the 2nd quarter worth about $42,000. Tower Research Capital LLC TRC lifted its holdings in shares of Lannett by 312.5% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,960 shares of the company’s stock worth $45,000 after acquiring an additional 3,000 shares during the period. Zacks Investment Management purchased a new position in shares of Lannett during the 2nd quarter worth about $65,000. Metropolitan Life Insurance Co NY purchased a new position in shares of Lannett during the 1st quarter worth about $77,000. Finally, Smith Asset Management Group LP purchased a new position in shares of Lannett during the 2nd quarter worth about $151,000.
Lannett Company Profile
Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages.
Featured Story: 52- Week Highs
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.